We are a pharmaceutical company invested and operated by a number of domestic and foreign pharmaceutical technology and regulatory experts, focusing on the development, production and commercialization of pharmaceutical preparations. AnBiSheng is committed to in line with the original drug quality and curative effect of high-end generic drugs research and development and production, dedicated to have clinical advantages of improved new drug research and development and production, is committed to internationalization of pharmaceutical preparations, specializing in industrial amplification, the production and quality assurance, in order to improve the drug accessibility, lower drug prices and for patients to provide more high-quality, low-price drug treatment.The invention patent has a montelukast sodium chewable tablet and a preparation method thereof
The invention relates to montelukast sodium tablet and a preparation method thereof
The invention relates to a solid dispersive sustained-release preparation of felodipine and a preparation method thereof
The invention relates to wellbutrin hydrochloride sustained release tablet and a preparation method thereof
Preparation process of solid preparation of clopidogrel hydrogen sulfate

Business scope: technology development, technology transfer, technology consultation, technology service in biological, chemical and medical professional fields, engaged in import and export of goods and technology import and export business (subject to approval according to law, subject to the approval of relevant departments).
The Team has been committed to high-end slow and controlled release drug technology research and development for European, American and domestic markets, and the development of patent challenging pharmaceutical preparations with independent intellectual property rights. At present, Ambisheng has a number of mature high-end preparation technology and production process, research products cover cardiovascular and cerebrovascular, respiratory tract, anti-depression and other treatment fields.
Over the past ten years, Ambisheng has achieved a total efficacy (bioequivalence) of
Target research and development characteristics. As a CRO (ContractResearchOrganization), as the domestic large pharmaceutical companies in Europe and the United States market development more than twenty drugs, 11 of them have been listed for approval.
At the same time, as the holder of drug marketing authorization in the United States, The Company actively carries out research and development and registration of its own drugs, including Montelukast sodium chewable tablets (specification: 4mg, 5mg) and Montelukast sodium tablets (specification: 10mg).
It has been approved by FDA.